한글목차

2024년에는 전 세계 16개국에서 370만 명 이상의 셀리악병(CD)으로 진단받는 유병자들이 예측되고 있습니다. 승인된 치료법이 없는 경우, CD의 유일한 치료는 엄격한 글루텐 제거 식이 요법을 따르는 것입니다. CD의 연구개발 활동은 완만하며 파이프라인에는 35개의 분자가 존재하며, 대부분 생물학적 제제입니다. 지난 10년간 미국은 CD의 임상시험시설이 가장 많았고 150곳 이상이었습니다. 지난 10년간 북미와 유럽에서는 인수가 가장 두드러진 거래 형태였습니다.

본 보고서에서는 세계의 셀리악병 시장에 대해 조사했으며, 질환의 개요와 함께, 임상시험 동향, 파이프라인 개요, 장래의 전망 등의 정보를 제공합니다.

목차

제1장 목차

제1장 서문

제2장 주요 조사 결과

제3장 병의 정세

• 질병의 개요
• 역학의 개요
• 치료 개요

제4장 발매가 끝난 약의 평가

• 주요 시판약
• 작용기전별 개요
• 분자 유형별 개요
• 제품 프로파일 및 매출 예측

제5장 가격 설정과 상환 평가

• 연간 치료비
• 가격 설정과 상환까지의 시간

제6장 파이프라인 의약품제의 평가

• 중기부터 후기 단계의 파이프라인 의약품제
• 개발 단계별 개요
• 작용기전별 개요
• 분자 유형별 개요
• 약물 고유의 상전이 성공률(PTSR) 및 승인 가능성(LoA)
• 치료 영역과 적응증별 PTSR과 LoA

제7장 임상시험 평가

• 역사적 개요
• 상별 개요
• 상태별 개요
• 진행중 및 계획중의 시험의 상별 개요
• 가상 컴포넌트 시험
• 지역의 시험 개요
• 지역별 단일국가 및 다국간 시험
• 상별 스폰서 상위 20사
• 스테이터스별 스폰서 상위 20사
• 엔드포인트 상태별 개요
• 인종과 민족별 개요
• 등록 데이터
• 임상시험시설 상위 20개국
• 세계의 톱 20 사이트
• 실현 가능성 분석 - 지리적 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래의 정세

제9장 상업적 평가

• 주요 시장 진출기업

제10장 장래 시장 성장 촉진요인

제11장 부록

영문목차

This reports provides a data-driven overview of the current and future competitive landscape in Celiac Disease therapeutics.

• In 2024, more than 3.7 million diagnosed prevalent cases of CD are anticipated in the 16 countries covered in GlobalData's epidemiology forecast.
• In absence of an approved therapy, the only treatment for CD is to follow a strict gluten-free diet.
• R&D activities for CD are moderate with 35 molecules in the pipeline, most of which are biologics present in early to mid-stage development.
• Over the past 10 years, the US has hosted the highest number of trial sites for CD, at more than 150 trial sites.
• During the past decade, acquisitions were the most prominent deal type in North America and Europe.

Scope

GlobalData's Celiac Disease: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Celiac Disease market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Celiac Disease market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer